Osthole improves therapy for osteoporosis through increasing autophagy of mesenchymal stem cells.

Osthole improves therapy for osteoporosis through increasing autophagy of mesenchymal stem cells. Exp Anim. 2019 Jun 03;: Authors: Zheng X, Yu Y, Shao B, Gan N, Chen L, Yang D Abstract Osteoporosis is a common skeletal disorder resulting in elevated fracture risk. Improvement of osteogenic differentiation is thought to be the top priority in osteoporosis treatment projects. Significant characteristics of bone marrow mesenchymal stem cells (BMMSCs), especially attractive ability to differentiate into osteoblasts, have made them alternatives for osteoporosis treatment. However, therapeutic effect with BMMSCs remains to be improved. Here, osthole, a bioactive simple coumarin derivative extracted from many medicinal plants, was introduced to pre-stimulate BMMSCs and then applied in osteoporosis therapy. The results showed that osthole-treated-BMMSCs (OBMMSCs) brought a better outcome than BMMSCs alone in estrogen deficiency-induced osteoporosis model. And elevated autophagy level was suggested to be the underlying mechanism of the ability of osthole to promote osteoblast differentiation, which is indicated by the upregulation of protein and mRNA expression level of autophagy-associated genes, Beclin1 and LC3. We concluded from these experiments that OBMMSCs are more effective than BMMSCs in osteoporosis treatment maybe through upregulation level of autophagy level induced by osthole. PMID: 31155553 [PubMed - as supplied by publis...
Source: Experimental Animals - Category: Research Tags: Exp Anim Source Type: research